Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BICOV-1: Combined Intraperitoneal Chemotherapy in Advanced Ovarian Cancer
NCT06902467Phase 1Recruiting
- Sponsor
- Fundación para la Formación e Investigación Sanitaria
- Start
- Feb 2023
- Primary completion
- Mar 2026
- Modality
- Nanoparticles, Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Cisplatin micelle injection (HA132) and Paclitaxel Micelles for Injection in ovarian cancer, sponsored by Fundación para la Formación e Investigación Sanitaria. Primary endpoint: Disease-free interval up to 5 years. Started Feb 2023; status: recruiting.
02
Drugs
Cisplatin micelle injection (HA132)Paclitaxel Micelles for Injection
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06902467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06902467.